Prima BioMed (NASDAQ:IMMP) Stock Passes Below 50 Day Moving Average – Here’s What Happened

Posted by Brian Himes on Aug 27th, 2026

Prima BioMed Ltd (NASDAQ:IMMP – Get Free Report)’s stock price crossed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $0.40 and traded as low as $0.38. Prima BioMed shares last traded at $0.3819, with a volume of 58,367 shares changing hands.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on IMMP shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Prima BioMed in a research report on Friday, July 10th. Maxim Group upgraded Prima BioMed from a “hold” rating to a “buy” rating in a report on Wednesday, June 17th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Prima BioMed has a consensus rating of “Hold” and an average target price of $5.50.

Get Our Latest Stock Analysis on Prima BioMed

Prima BioMed Price Performance

The business’s 50-day moving average is $0.40 and its two-hundred day moving average is $0.83.

Hedge Funds Weigh In On Prima BioMed

A hedge fund recently raised its position in Prima BioMed stock. Jane Street Group LLC grew its stake in shares of Prima BioMed Ltd (NASDAQ:IMMP – Free Report) by 14.7% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 51,574 shares of the biotechnology company’s stock after purchasing an additional 6,617 shares during the quarter. Jane Street Group LLC’s holdings in Prima BioMed were worth $91,000 at the end of the most recent quarter. Institutional investors and hedge funds own 2.32% of the company’s stock.

About Prima BioMed

(Get Free Report)

Prima BioMed, trading as IMMP on NASDAQ, is a clinical-stage biotechnology company specializing in the development of immunotherapy products for cancer treatment. The company’s core technology platform centers on targeting the lymphocyte activation gene-3 (LAG-3), a checkpoint receptor that modulates T-cell activity. Prima BioMed’s lead candidate, eftilagimod alpha (IMP321), is a soluble LAG-3 protein designed to enhance antigen-presenting cell function and stimulate a tumor-specific immune response.